Becton Dickinson and Co (NYSE:BDX) – Stock analysts at Leerink Swann issued their Q1 2019 EPS estimates for shares of Becton Dickinson and in a note issued to investors on Wednesday, November 7th. Leerink Swann analyst R. Newitter expects that the medical instruments supplier will post earnings of $2.65 per share for the quarter. Leerink Swann also issued estimates for Becton Dickinson and’s Q2 2019 earnings at $2.86 EPS, Q3 2019 earnings at $3.27 EPS and Q4 2019 earnings at $3.31 EPS.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, hitting analysts’ consensus estimates of $2.93. The company had revenue of $4.40 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The firm’s revenue was up 39.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.40 earnings per share.

Several other analysts have also recently issued reports on BDX. KeyCorp reiterated a “buy” rating and issued a $264.00 price objective on shares of Becton Dickinson and in a research note on Friday, August 3rd. Royal Bank of Canada reiterated a “hold” rating and issued a $248.00 price objective on shares of Becton Dickinson and in a research note on Friday, August 3rd. Citigroup increased their price objective on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. Wells Fargo & Co increased their price objective on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a research note on Thursday, September 6th. They noted that the move was a valuation call. Finally, Morgan Stanley increased their price objective on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a research note on Thursday, October 4th. Five investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $254.07.

Shares of NYSE BDX opened at $243.26 on Friday. The firm has a market capitalization of $63.38 billion, a PE ratio of 22.09, a P/E/G ratio of 1.46 and a beta of 1.19. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23. Becton Dickinson and has a 12-month low of $209.91 and a 12-month high of $265.87.

A number of large investors have recently bought and sold shares of BDX. Acropolis Investment Management LLC purchased a new position in shares of Becton Dickinson and during the third quarter worth about $101,000. Almanack Investment Partners LLC. purchased a new position in shares of Becton Dickinson and during the second quarter worth about $105,000. Truvestments Capital LLC purchased a new position in shares of Becton Dickinson and during the third quarter worth about $105,000. Bartlett & Co. LLC grew its holdings in shares of Becton Dickinson and by 2,900.0% during the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock worth $108,000 after purchasing an additional 435 shares during the last quarter. Finally, Bridgeworth LLC purchased a new position in shares of Becton Dickinson and during the second quarter worth about $131,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director Timothy M. Ring sold 42,000 shares of the stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total value of $9,956,940.00. Following the transaction, the director now owns 93,688 shares of the company’s stock, valued at $22,210,614.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP James C. Lim sold 5,189 shares of the stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $242.36, for a total value of $1,257,606.04. Following the completion of the transaction, the executive vice president now directly owns 13,318 shares in the company, valued at approximately $3,227,750.48. The disclosure for this sale can be found here. Corporate insiders own 1.00% of the company’s stock.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Story: What is a Market Correction?

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.